Predictors of remission in people with axial spondyloarthritis: A systematic literature review

van der Heijde, 2017, 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Ann Rheum Dis, 76, 978, 10.1136/annrheumdis-2016-210770 Smolen, 2018, Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force, Ann Rheum Dis, 77, 3, 10.1136/annrheumdis-2017-211734 Wendling, 2015, Treating to target in axial spondyloarthritis: defining the target and the arrow, Expert Rev Clin Immunol, 11, 691, 10.1586/1744666X.2015.1039514 Machado, 2011, How to measure disease activity in axial spondyloarthritis?, Curr Opin Rheumatol, 23, 339, 10.1097/BOR.0b013e3283470f23 Machado, 2019, Treat-to-target in axial spondyloarthritis: gold standard or fools' gold?, Curr Opin Rheumatol, 31, 344, 10.1097/BOR.0000000000000625 Machado, 2014, Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis, Best Pract Res Clin Rheumatol, 28, 711, 10.1016/j.berh.2014.10.004 Baraliakos, 2018, Challenges and advances in targeting remission in axial spondyloarthritis, J Rheumatol, 45, 153, 10.3899/jrheum.170222 Anderson, 2001, Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis, Arthritis Rheum, 44, 1876, 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F van der Heijde, 2009, ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis, Ann Rheum Dis, 68, 1811, 10.1136/ard.2008.100826 Machado, 2011, Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores, Ann Rheum Dis, 70, 47, 10.1136/ard.2010.138594 Machado, 2015, Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort, Arthritis Rheumatol, 67, 408, 10.1002/art.38921 Machado, 2018, Assessment of spondyloarthritis international S. ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states, Ann Rheum Dis, 77, 1539, 10.1136/annrheumdis-2018-213184 Ramiro, 2014, Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort, Ann Rheum Dis, 73, 1455, 10.1136/annrheumdis-2014-205178 Poddubnyy, 2016, High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German SPondyloarthritis Inception Cohort, Ann Rheum Dis, 75, 2114, 10.1136/annrheumdis-2016-209209 Molnar, 2018, TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort, Ann Rheum Dis, 77, 63, 10.1136/annrheumdis-2017-211544 van der Heijde, 2014, The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial, J Rheumatol, 41, 1095, 10.3899/jrheum.131003 van der Heijde, 2016, ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis, Rheumatology (Oxford), 55, 80, 10.1093/rheumatology/kev267 Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for systematic reviews of interventions version 6.0 (updated July 2019): Cochrane; 2019. Available from: www.training.cochrane.org/handbook. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, J Clin Epidemiol, 62, e1, 10.1016/j.jclinepi.2009.06.006 Hayden, 2013, Assessing bias in studies of prognostic factors, Ann Intern Med, 158, 280, 10.7326/0003-4819-158-4-201302190-00009 Rudwaleit, 2009, Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis, J Rheumatol, 36, 801, 10.3899/jrheum.081048 Maksymowych, 2010, Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics, Arthritis Care Res, 62, 826, 10.1002/acr.20131 Sieper, 2012, Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis, Ann Rheumatic Dis, 71, 700, 10.1136/annrheumdis-2011-200358 Sieper, 2016, Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics, Rheumatology (Oxford), 55, 1946, 10.1093/rheumatology/kew230 Landewe, 2018, Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study, Lancet, 392, 134, 10.1016/S0140-6736(18)31362-X Sieper, 2019, Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study, RMD Open, 5, 10.1136/rmdopen-2019-000917 Magrey, 2021 Baraliakos, 2015, Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials, J Rheumatol, 42, 1418, 10.3899/jrheum.141278 Vastesaeger, 2011, Predicting the outcome of ankylosing spondylitis therapy, Ann Rheum Dis, 70, 973, 10.1136/ard.2010.147744 Benavent, 2022, Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain, BMJ Open, 12, 10.1136/bmjopen-2021-057850 Nam, 2021, Early improvements in disease activity indices predict long-term clinical remission suggested by the treat-to-target strategy in patients with ankylosing spondylitis receiving TNF-α inhibitor treatment, J Clin Med, 10, 4279, 10.3390/jcm10184279 Glintborg, 2010, Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry, Ann Rheum Dis, 69, 2002, 10.1136/ard.2009.124446 Shimabuco, 2018, Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors, Adv Rheumatol, 58, 40, 10.1186/s42358-018-0040-x Paccou, 2012, Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice, J Rheumatol, 39, 1418, 10.3899/jrheum.111337 Hernández-Breijo, 2019, Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis, Arthritis Res Ther, 21, 1, 10.1186/s13075-019-1849-3 Pina Vegas, 2021, Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort, Rheumatology (Oxford) Iannone, 2018, Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings, Eur J Clin Invest, 48, e13013, 10.1111/eci.13013 Yahya, 2018, Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-Findings from a United Kingdom cohort, Rheumatology (United Kingdom), 57, 619, 10.1093/rheumatology/kex457 Lubrano, 2018, The sex influence on response to tumor necrosis factor-alpha inhibitors and remission in axial spondyloarthritis, J Rheumatol, 45, 195, 10.3899/jrheum.17666 Ruyssen-Witrand, 2022, Factors associated with drug-free remission at 5 year in early onset axial spondyloarthritis patients: data from the DESIR cohort, Joint Bone Spine, 10.1016/j.jbspin.2022.105358 Molto, 2018, Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study, Ann Rheum Dis, 77, 533, 10.1136/annrheumdis-2017-212378 Sieper, 2014, Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1, Ann Rheum Dis, 73, 101, 10.1136/annrheumdis-2012-203201 Arends, 2011, Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study, Arthritis Res Ther, 13, R94, 10.1186/ar3369